This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Based in New Haven, CT, Alexion Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of life-transforming drugs, for the treatment of patients with ultra-rare disorders. The company’s complement franchise consists of key growth driver, Soliris, which is approved for the treatment of two severe and ultra-rare disorders resulting from chronic uncontrolled activation of the complement component of the immune system — paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Soliris is also approved for the treatment of generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive. The FDA also approved its long-acting C5 complement inhibitor, Ultomiris, for the treatment of adult patients with PNH, to be administered every eight weeks. In October 2019, the FDA approved the use of Ultomiris as a treatment for adult and pediatric (one month of age or older) patients with aHUS to inhibit complement-mediated TMA.
Will Trikafta Drive Vertex's (VRTX) Revenues in Q4 Earnings?
by Zacks Equity Research
On Vertex's (VRTX) fourth-quarter earnings call, investor focus will be on the sales performance of its triple combo CF drug Trikafta.
Vertex's (VRTX) Trikafta NDA Gets Priority Review by FDA
by Zacks Equity Research
Vertex's (VRTX) sNDA seeking approval for Trikafta to treat cystic fibrosis in children has been accepted by the FDA.
ALXN vs. BMRN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ALXN vs. BMRN: Which Stock Is the Better Value Option?
J&J (JNJ) Q4 Earnings & Sales Beat, 2021 Guidance Upbeat
by Zacks Equity Research
J&J (JNJ) beats fourth-quarter 2020 estimates for both earnings and sales. It issues its adjusted earnings and sales outlook for 2021. Stock up.
BioCryst (BCRX) Wins Japanese Approval for HAE Drug Orladeyo
by Zacks Equity Research
BioCryst (BCRX) gets approval in Japan for oral, once-daily Orladeyo 150 mg for prophylactic treatment of hereditary angioedema (HAE) in adults and pediatric patients 12 years or older.
Ultragenyx's (RARE) IND for Wilson Disease Cleared by FDA
by Zacks Equity Research
Ultragenyx's (RARE) IND application for UX701 for the treatment of Wilson Disease gets FDA clearance.
5 Finest PEG Stocks for GARP Investors
by Urmimala Biswas
Here are five picks out of 45 top-ranked stocks with discounted PEG.
Will Alexion (ALXN) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Alexion (ALXN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Roche's (RHHBY) Esbriet sNDA Gets Priority Review From FDA
by Zacks Equity Research
The FDA accepts Roche's (RHHBY) sNDA for Esbriet under a priority review to treat unclassifiable interstitial lung disease. A verdict from the regulatory body is awaited in May 2021.
AstraZeneca's (AZN) Enhertu Gets EU Nod for Breast Cancer
by Zacks Equity Research
AstraZeneca's (AZN) Enhertu gets EU approval for metastatic HER2-positive breast cancer patients who have received two or more prior anti-HER2-based regimens.
Cocrystal Pharma (COCP) Completes Research Obligations With Merck
by Zacks Equity Research
Cocrystal (COCP) completes all research obligations under the Merck exclusive worldwide license and collaboration agreement.
Biotech Stock Roundup: ALXN Pauses Study, ACRS & GRTS Surge, & Other Updates
by Zacks Equity Research
The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Alexion (ALXN), Aclaris (ACRS) and Biohaven (BHVN).
AstraZeneca's (AZN) Enhertu Gets FDA Nod for Gastric Cancer
by Zacks Equity Research
AstraZeneca's (AZN) Enhertu is the first HER2-directed medicine approved in a decade for patients with HER2-positive metastatic gastric cancer.
Zacks.com featured highlights include: Alexion Pharmaceuticals, Adient, Affiliated Managers Group and General Motors
by Zacks Equity Research
Zacks.com featured highlights include: Alexion Pharmaceuticals, Adient, Affiliated Managers Group and General Motors
Pfizer's (PFE) Xalkori Gets FDA Nod for Rare Lymphoma in Kids
by Zacks Equity Research
FDA approves Pfizer's (PFE) Xalkori for relapsed or refractory ALK-positive anaplastic large cell lymphoma, a rare form of non-Hodgkin lymphoma (NHL), in pediatric patients and young adults.
Alexion (ALXN) to Pause Enrollment in COVID-19 Study on Ultomiris
by Zacks Equity Research
Alexion (ALXN) decides to stop further enrollment in the late-stage study of Ultomiris in adults with severe COVID-19 requiring mechanical ventilation due to lack of efficacy.
4 Promising Price-to-Book Value Stocks to Buy Now
by Kinjel Shah
P/B ratio is emerging as a convenient tool to identify low-priced stocks that have high growth prospects.
AbbVie (ABBV) Inks Deal to Acquire Medical Device Company
by Zacks Equity Research
AbbVie (ABBV) signs an agreement to acquire privately held Cypris Medical, including the latter's Xact device which is used for performing face and neck lifts.
Merck (MRK) Gets Priority Tag for Pneumococcal Vaccine BLA
by Zacks Equity Research
Merck's (MRK) investigational 15-valent pneumococcal conjugate vaccine, V114 includes pneumococcal serotypes 22F and 33F, which are not included in the currently licensed conjugate vaccines.
Sanofi (SNY) to Acquire Kymab to Boost Immunology Presence
by Zacks Equity Research
Sanofi's (SNY) potential acquisition of Kymab, a private biotech, is set to strengthen its presence in immunology.
ALXN or BMRN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ALXN vs. BMRN: Which Stock Is the Better Value Option?
Apellis' (APLS) Pipeline Candidate Pegcetacoplan Promising
by Zacks Equity Research
Apellis' (APLS) lead pipeline candidate, pegcetacoplan, is a promising one and being developed for several indications.
5 Biotech Stocks That More Than Doubled This Year
by Ekta Bagri
The biotech sector has been in focus through 2020 as companies like Moderna (MRNA) strive hard to develop a vaccine for COVID-19.
Pharma Stock Roundup: FDA Emergency Nod to PFE/BNTX COVID-19 Vaccine, AZN to Buy ALXN
by Kinjel Shah
FDA grants approval for emergency use of Pfizer's (PFE) COVID-19 vaccine. AstraZeneca (AZN) offers to buy Alexion.
Biotech Stock Roundup: ALXN Up on Acquisition News, PFE-BNTX Get EUA for Vaccine & More
by Zacks Equity Research
Coronavirus vaccine updates from Moderna (MRNA) and Pfizer (PFE)/BioNTech (BNTX) and Alexion's (ALXN) acquisition grab headlines this week.